BioSpace News Archive

CVS Health has formally launched its COVID-19 vaccination program for long-term care facilities, whose residents have been disproportionality impacted by the pandemic.

- Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 Billion plus royalties - Includes Agios’ marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier’s strategic ambition to become a recognized and innovative player in oncology, supported by unique drug discovery capabilities

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the initiation of a rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy

Bristol Myers Squibb (NYSE:BMY) will announce results for the fourth quarter of 2020 on Thursday, February 4, 2021.

AstraZeneca’s TAGRISSO® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent.

Kit Can Allow More People to Get Tested, Helping Reduce the Spread of the Virus and Improving the Health of Communities

Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating Officer Amy Schulman stepping down from Board of Directors

Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies,

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress at the 39th Annual J.P. Morgan Healthcare Conference

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and development and chief medical officer. Dr. Thomas joins Equillium from Principia Biopharma (recently acquired by Sanofi) where she was chief medical officer focused on developing treatments for immu